Jonathan Brody

TitleProfessor
InstitutionThomas Jefferson University
DepartmentSurgery
Address1015 Walnut St.
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Schultz CW, Ruiz de Garibay G, Langer A, Liu JB, Dhir T, Leitch C, Wessner CE, Mayoral M, Zhang B, Popa M, Huang C, Kotopoulis S, Luo X, Zhen Y, Niu S, Torkzaban M, Wallace K, Eisenbrey JR, Brody JR, McCormack E, Forsberg F. Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model. Cancer Biol Ther. 2021 Mar 04; 22(3):204-215. PMID: 33691611.
      Citations:    
    2. Haber AO, Jain A, Mani C, Nevler A, Agostini LC, Golan T, Palle K, Yeo CJ, Gmeiner WH, Brody JR. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. Mol Cancer Res. 2021 Apr; 19(4):565-572. PMID: 33593942.
      Citations:    
    3. Gmeiner WH, Dominijanni A, Haber AO, Ghiraldeli LP, Caudell DL, D Agostino R, Pasche BC, Smith TL, Deng Z, Kiren S, Mani C, Palle K, Brody JR. Improved anti-Tumor Activity of the Fluoropyrimidine Polymer CF10 in pre-Clinical Colorectal Cancer Models thru Distinct Mechanistic and Pharmacological Properties. Mol Cancer Ther. 2020 Dec 23. PMID: 33361273.
      Citations:    
    4. Agostini LC, Jain A, Shupp A, Nevler A, McCarthy G, Bussard KM, Yeo CJ, Brody JR. Combined targeting of PARG and Wee1 causes decreased cell survival and DNA damage in an S-phase dependent manner. Mol Cancer Res. 2020 Nov 30. PMID: 33257507.
      Citations:    
    5. Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 Jul 15. PMID: 32669374.
      Citations:    
    6. Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, Petricoin EF. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020 Apr; 21(4):508-518. PMID: 32135080.
      Citations:    
    7. Nevler A, Brown SZ, Nauheim D, Portocarrero C, Bassig J, Schultz CW, McCarthy G, Lavu H, Yeo TP, Yeo CJ, Brody JR. Effect of Hypercapnia, an Element of Obstructive Respiratory Disorders, on Pancreatic Cancer Chemoresistance and Progression. J Am Coll Surg. 2020 Feb 10. PMID: 32058016.
      Citations:    
    8. Lowder CY, Dhir T, Goetz AB, Thomsett HL, Bender J, Tatarian T, Madhavan S, Petricoin EF, Blais E, Lavu H, Winter JM, Posey J, Brody JR, Pishvaian MJ, Yeo CJ. A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience. Surg Oncol. 2020 Jun; 33:118-125. PMID: 32561076.
      Citations:    
    9. Schultz CW, Preet R, Dhir T, Dixon DA, Brody JR. Understanding and targeting the disease-related RNA binding protein human antigen R (HuR). Wiley Interdiscip Rev RNA. 2020 Jan 23; e1581. PMID: 31970930.
      Citations:    
    10. Brown SZ, Agostini LC, Thomsett HL, Brody JR. Ultra-fast conductive media for RNA electrophoretic mobility shift assays. Biotechniques. 2019 Dec 24. PMID: 31870164.
      Citations:    
    11. Armstrong SA, Schultz CW, Azimi-Sadjadi A, Brody JR, Pishvaian MJ. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Mol Cancer Ther. 2019 11; 18(11):1899-1908. PMID: 31676541.
      Citations:    
    12. Dhir T, Schultz CW, Jain A, Brown SZ, Haber A, Goetz A, Xi C, Su GH, Xu L, Posey J, Jiang W, Yeo CJ, Golan T, Pishvaian MJ, Brody JR. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Mol Cancer Res. 2019 Aug 05. PMID: 31383722.
      Citations:    
    13. Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. Br J Cancer. 2019 Jul; 121(3):264-270. PMID: 31292535.
      Citations:    
    14. Jain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, Cozzitorto J, Schultz CW, Lowder CY, Smith KM, Waddell ID, Raitses-Gurevich M, Stossel C, Gorman YG, Atias D, Yeo CJ, Winter JM, Olive KP, Golan T, Pishvaian MJ, Ogilvie D, James DI, Jordan AM, Brody JR. Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer. Cancer Res. 2019 Jul 04. PMID: 31273064.
      Citations:    
    15. Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C. The Sustained Induction of c-MYC Drives Nab-paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Mol Cancer Res. 2019 Jun 04. PMID: 31164413.
      Citations:    
    16. Tesfaye AA, Wang H, Hartley ML, He AR, Weiner L, Gabelia N, Kapanadze L, Shezad M, Brody JR, Marshall JL, Pishvaian MJ. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. J Pancreat Cancer. 2019; 5(1):12-21. PMID: 31065624.
      Citations:    
    17. Vaziri-Gohar A, Zarei M, Brody JR, Winter JM. Corrigendum: Metabolic Dependencies in Pancreatic Cancer. Front Oncol. 2018; 8:672. PMID: 30805300.
      Citations:    
    18. Jain A, Brown SZ, Thomsett HL, Londin E, Brody JR. Evaluation of Post-transcriptional Gene Regulation in Pancreatic Cancer Cells: Studying RNA Binding Proteins and Their mRNA Targets. Methods Mol Biol. 2019; 1882:239-252. PMID: 30378060.
      Citations:    
    19. Vaziri-Gohar A, Zarei M, Brody JR, Winter JM. Metabolic Dependencies in Pancreatic Cancer. Front Oncol. 2018; 8:617. PMID: 30631752.
      Citations:    
    20. Bauer TM, Dhir T, Strickland A, Thomsett H, Goetz AB, Cannaday S, Brody JR, Pishvaian MJ, Yeo CJ. Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure. J Pancreat Cancer. 2018; 4(1):81-87. PMID: 30788462.
      Citations:    
    21. Zarei M, Lal S, Vaziri-Gohar A, O'Hayer K, Gunda V, Singh PK, Brody JR, Winter JM. RNA-binding Protein HuR Regulates Both Mutant and Wild-type IDH1 in IDH1-mutated Cancer. Mol Cancer Res. 2018 Sep 28. PMID: 30266754.
      Citations:    
    22. Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis MT, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, Yeo CJ, Prendergast GC, Brody JR. Host IDO2 gene status influences tumor progression and radiotherapy response in KRAS-driven sporadic pancreatic cancers. Clin Cancer Res. 2018 Sep 28. PMID: 30266763.
      Citations:    
    23. Pan H, Strickland A, Madhu V, Johnson ZI, Chand SN, Brody JR, Fertala A, Zheng Z, Shapiro IM, Risbud MV. RNA binding protein HuR regulates extracellular matrix gene expression and pH homeostasis independent of controlling HIF-1a signaling in nucleus pulposus cells. Matrix Biol. 2018 Aug 07. PMID: 30092282.
      Citations:    
    24. Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol. 2018; 2018. PMID: 30234181.
      Citations:    
    25. Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF. Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative. Clin Cancer Res. 2018 Jun 28. PMID: 29954777.
      Citations:    
    26. Yeo TP, Lavu H, Nevler A, Brumbaugh J, Vicchairelli D, Winter JM, Brody JR, Yeo CJ. Precious Data: Interim Report from the Jefferson Pancreas Tumor Registry. J Pancreat Cancer. 2018; 4(1):17-24. PMID: 30631853.
      Citations:    
    27. Tiriac H, Belleau P, Engle DD, Plenker D, DeschĂȘnes A, Somerville T, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JA, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, Lecomte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson ED, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen PJ, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim EJ, Crawford JM, Devoe CE, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt RA, Knox JJ, Krasnitz A, Gallinger S, Tuveson DA. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018 May 31. PMID: 29853643.
      Citations:    
    28. Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. 2018 Mar 26. PMID: 29579325.
      Citations:    
    29. Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. Clin Cancer Res. 2018 Feb 26. PMID: 29483142.
      Citations:    
    30. Brody JR, Dixon DA. Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA. 2018 Feb 16. PMID: 29452455.
      Citations:    
    31. Nevler A, Muller AJ, Cozzitorto JA, Goetz A, Winter JM, Yeo TP, Lavu H, Yeo CJ, Prendergast GC, Brody JR. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg. 2018 Feb 07. PMID: 29426021.
      Citations:    
    32. Peng W, Furuuchi N, Aslanukova L, Huang YH, Brown SZ, Jiang W, Addya S, Vishwakarma V, Peters E, Brody JR, Dixon DA, Sawicki JA. Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol. 2018 Feb 01; 38(3). PMID: 29133460.
      Citations:    
    33. Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR. Post-transcriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors. Cancer Res. 2017 Jul 07. PMID: 28687616.
      Citations:    
    34. Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, Mambelli-Lisboa NC, Moffat C, Blanco FF, Chand SN, Jimbo M, Cozzitorto JA, Jiang W, Yeo CJ, Londin E, Seifert EL, Metallo CM, Brody JR, Winter JM. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Res. 2017 Jun 26. PMID: 28652247.
      Citations:    
    35. Pishvaian MJ, Brody JR. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer. Oncology (Williston Park). 2017 Mar 15; 31(3):159-66, 168. PMID: 28299752.
      Citations:    
    36. Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer. 2017 Apr 11; 116(8):1021-1026. PMID: 28291774.
      Citations:    
    37. Jinawath N, Shiao MS, Norris A, Murphy K, Klein AP, Yonescu R, Iacobuzio-Donahue C, Meeker A, Jinawath A, Yeo CJ, Eshleman JR, Hruban RH, Brody JR, Griffin CA, Harada S. Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas. Genes Chromosomes Cancer. 2017 May; 56(5):427-435. PMID: 28124395.
      Citations:    
    38. Lal S, Cheung EC, Zarei M, Preet R, Chand SN, Mambelli-Lisboa NC, Romeo C, Stout MC, Londin E, Goetz A, Lowder CY, Nevler A, Yeo CJ, Campbell PM, Winter JM, Dixon DA, Brody JR. CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Mol Cancer Res. 2017 Jun; 15(6):696-707. PMID: 28242812.
      Citations:    
    39. Rao S, Beckman RA, Riazi S, Yabar CS, Boca SM, Marshall JL, Pishvaian MJ, Brody JR, Madhavan S. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget. 2016 Nov 24. PMID: 27888622.
      Citations:    
    40. Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Ann Surg. 2016 Nov 23. PMID: 27893535.
      Citations:    
    41. Blanco FF, Preet R, Aguado A, Vishwakarma V, Stevens LE, Vyas A, Padhye S, Xu L, Weir SJ, Anant S, Meisner-Kober N, Brody JR, Dixon DA. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget. 2016 Nov 08; 7(45):74043-74058. PMID: 27677075.
      Citations:    
    42. Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E, Brody JR. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget. 2017 Oct 13; 8(48):83446-83456. PMID: 29137355.
      Citations:    
    43. Lal S, Zarei M, Chand SN, Dylgjeri E, Mambelli-Lisboa NC, Pishvaian MJ, Yeo CJ, Winter JM, Brody JR. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Sci Rep. 2016; 6:33323. PMID: 27616351.
      Citations:    
    44. Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E, Fortuna D, Curtis M, Wang ZX, Pishvaian MJ, Winter JM. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biol Ther. 2016 Jul 28; 0. PMID: 27466707.
      Citations:    
    45. Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget. 2016 Apr 19; 7(16):21812-24. PMID: 26943573.
      Citations:    
    46. Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Mol Cancer Res. 2016 Jul; 14(7):599-611. PMID: 27053682.
      Citations:    
    47. Huang YH, Peng W, Furuuchi N, Gerhart J, Rhodes K, Mukherjee N, Jimbo M, Gonye GE, Brody JR, Getts RC, Sawicki JA. Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth. Cancer Res. 2016 Mar 15; 76(6):1549-59. PMID: 26921342.
      Citations:    
    48. O Hayer KM, Brody JR. Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both? Discov Med. 2016 Feb; 21(114):117-23. PMID: 27011047.
      Citations:    
    49. Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int J Biol Sci. 2016; 12(3):273-82. PMID: 26929734.
      Citations:    
    50. Weinberg BA, Yabar CS, Brody JR, Pishvaian MJ. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma. Oncology (Williston Park). 2015 Nov; 29(11). PMID: 26573060.
      Citations:    
    51. Jimbo M, Blanco FF, Huang YH, Telonis AG, Screnci BA, Cosma GL, Alexeev V, Gonye GE, Yeo CJ, Sawicki JA, Winter JM, Brody JR. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget. 2015 Sep 29; 6(29):27312-31. PMID: 26314962.
      Citations:    
    52. Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology. 2016 Jan; 150(1):48-63. PMID: 26385075.
      Citations:    
    53. Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget. 2015 Jun 30; 6(18):15788-801. PMID: 26158861.
      Citations:    
    54. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A. 2015 Mar 10; 112(10):E1106-15. PMID: 25713380.
      Citations:    
    55. Cozzitorto JA, Jimbo M, Chand S, Blanco F, Lal S, Gilbert M, Winter JM, Gorospe M, Brody JR. Studying RNA-Binding Protein Interactions with Target mRNAs in Eukaryotic Cells: Native Ribonucleoprotein Immunoprecipitation (RIP) Assays. Methods Mol Biol. 2015; 1262:239-46. PMID: 25555585.
      Citations:    
    56. Kozak G, Blanco FF, Brody JR. Novel targets in pancreatic cancer research. Semin Oncol. 2015 Feb; 42(1):177-87. PMID: 25726061.
      Citations:    
    57. Chand SN, Blanco FF, Jimbo M, Tsangaris TN, Cristofanilli M, Yeo CJ, Winter JM, Pishvaian MJ, Brody JR. PARP Inhibitors for Chemoprevention-Letter. Cancer Prev Res (Phila). 2014 Nov; 7(11):1170-1. PMID: 25368011.
      Citations:    
    58. Tholey RM, Lal S, Jimbo M, Burkhart RA, Blanco FF, Cozzitorto JA, Eisenberg JD, Jiang W, Iacobuzio-Donahue CA, Witkiewicz AK, Glbert M, Yeo CJ, Brody JR, Sawicki JA, Winter JM. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Mol Cancer Res. 2015 Mar; 13(3):439-48. PMID: 25336517.
      Citations:    
    59. Blanco FF, Pishvaian MJ, Brody JR. Upgrading gemcitabine with recycled kinase inhibitors. Cell Cycle. 2014 Sep 15; 13(18):2810-1. PMID: 25486467.
      Citations:    
    60. Jimbo M, Knudsen KE, Brody JR. Fusing transcriptomics to progressive prostate cancer. Am J Pathol. 2014 Oct; 184(10):2608-10. PMID: 25128905.
      Citations:    
    61. Clark PM, Loher P, Quann K, Brody J, Londin ER, Rigoutsos I. Argonaute CLIP-Seq reveals miRNA targetome diversity across tissue types. Sci Rep. 2014; 4:5947. PMID: 25103560.
      Citations:    
    62. McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, de Jesus Acosta A, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: A dual-institutional follow-up with the RTOG 9704 trial. Cancer Biol Ther. 2014 Jun 1; 15(6):688-98. PMID: 24618665.
      Citations:    
    63. Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR. HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells. Cancer Res. 2014 Feb 15; 74(4):1128-40. PMID: 24536047.
      Citations:    
    64. Steffen JD, Brody JR, Armen RS, Pascal JM. Structural Implications for Selective Targeting of PARPs. Front Oncol. 2013; 3:301. PMID: 24392349.
      Citations:    
    65. Steffen JD, Tholey RM, Langelier MF, Planck JL, Schiewer MJ, Lal S, Bildzukewicz NA, Yeo CJ, Knudsen KE, Brody JR, Pascal JM. Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer. Cancer Res. 2014 Jan 1; 74(1):31-7. PMID: 24189460.
      Citations:    
    66. Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol. 2013 Aug 1; 10(8):1312-23. PMID: 23807417.
      Citations:    
    67. Burkhart RA, Peng Y, Norris ZA, Tholey RM, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, Sawicki JA, Zhuang Z, Brody JR. Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival. Mol Cancer Res. 2013 Aug; 11(8):901-11. PMID: 23696131.
      Citations:    
    68. Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R, Felsher DW, DiMaio DJ, Hollingsworth MA, Morris JP, Hebrok M, Witkiewicz AK, Brody JR, Rui H, Wagner KU. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res. 2013 Mar 15; 73(6):1821-30. PMID: 23467612.
      Citations:    
    69. Tholey R, Sawicki JA, Brody JR. Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box". Cancer J. 2012 Nov; 18(6):665-73. PMID: 23187855.
      Citations:    
    70. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng FY, Knudsen KE. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012 Dec; 2(12):1134-49. PMID: 22993403.
      Citations:    
    71. Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin ER, Rigoutsos I, Yeo CJ, Gorospe M, Witkiewicz AK, Sachs JN, Brody JR. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. Cancer Biol Ther. 2012 Aug; 13(10):946-55. PMID: 22785201.
      Citations:    
    72. Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, Jia X, Qin LX, D'Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR, O'Reilly EM, Allen PJ. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One. 2012; 7(7):e40157. PMID: 22792233.
      Citations:    
    73. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013 Jan; 107(1):15-22. PMID: 22729569.
      Citations:    
    74. Valley CC, Lewis AK, Mudaliar DJ, Perlmutter JD, Braun AR, Karim CB, Thomas DD, Brody JR, Sachs JN. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J Biol Chem. 2012 Jun 15; 287(25):21265-78. PMID: 22496450.
      Citations:    
    75. Valsecchi ME, Holdbrook T, Leiby BE, Pequignot E, Littman SJ, Yeo CJ, Brody JR, Witkiewicz AK. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer. 2012; 12:104. PMID: 22436573.
      Citations:    
    76. Wu KN, Queenan M, Brody JR, Potoczek M, Sotgia F, Lisanti MP, Witkiewicz AK. Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle. 2011 Dec 15; 10(24):4250-5. PMID: 22134245.
      Citations:    
    77. Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, Yeo CJ, Solomides C, Peiper SC, Witkiewicz AK. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012 Jul 15; 118(14):3484-93. PMID: 22086503.
      Citations:    
    78. Talbott VA, Yeo CJ, Brody JR, Witkiewicz AK. Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient. J Surg Res. 2012 Jul; 176(1):154-8. PMID: 22118834.
      Citations:    
    79. Rittenhouse DW, Talbott VA, Anklesaria Z, Brody JR, Witkiewicz AK, Yeo CJ. Subject review: pancreatic ductal adenocarcinoma in the setting of mutations in the cystic fibrosis transmembrane conductance regulator gene: case report and review of the literature. J Gastrointest Surg. 2011 Dec; 15(12):2284-90. PMID: 21809164.
      Citations:    
    80. Witkiewicz AK, Kline J, Queenan M, Brody JR, Tsirigos A, Bilal E, Pavlides S, Ertel A, Sotgia F, Lisanti MP. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle. 2011 Jun 1; 10(11):1794-809. PMID: 21521946.
      Citations:    
    81. Brody JR, Witkiewicz AK, Yeo CJ. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Adv Surg. 2011; 45:301-21. PMID: 21954696.
      Citations:    
    82. Brody JR, Gonye GE. HuR's role in gemcitabine efficacy: an exception or opportunity? Wiley Interdiscip Rev RNA. 2011 May; 2(3):435-44. PMID: 21957028.
      Citations:    
    83. Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, Gonye GE, Yeo CJ, Witkiewicz AK, Brody JR. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One. 2010; 5(11):e15455. PMID: 21152064.
      Citations:    
    84. Huang YH, Cozzitorto JA, Richards NG, Eltoukhy AA, Yeo CJ, Langer R, Anderson DG, Brody JR, Sawicki JA. CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapy. Cancer Biol Ther. 2010 Nov 23; 10(9):878-84. PMID: 20798601.
      Citations:    
    85. Brody JR, Witkiewicz AK. CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancers. Cancer Biol Ther. 2010 Sep; 10(6):615-6. PMID: 20686361.
      Citations:    
    86. Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg. 2010 Sep; 252(3):499-505; discussion 505-6. PMID: 20739850.
      Citations:    
    87. Witkiewicz AK, Freydin B, Chervoneva I, Potoczek M, Rizzo W, Rui H, Brody JR, Schwartz GF, Lisanti MP. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther. 2010 Aug; 10(4):391-6. PMID: 20574156.
      Citations:    
    88. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, Sotgia F, Brody JR, Mitchell EP, Lisanti MP. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther. 2010 Jul; 10(2):135-43. PMID: 20431349.
      Citations:    
    89. Toll AD, Dasgupta A, Potoczek M, Yeo CJ, Kleer CG, Brody JR, Witkiewicz AK. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol. 2010 Sep; 41(9):1205-9. PMID: 20573371.
      Citations:    
    90. Showalter SL, Charles S, Belin J, Cozzitorto J, Einstein P, Richards NG, Sauter PK, Kennedy EP, Witkiewicz A, Brody JR, Yeo CJ. Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opin Drug Deliv. 2010 Mar; 7(3):273-84. PMID: 20201734.
      Citations:    
    91. Showalter SL, Wang Z, Costantino CL, Witkiewicz AK, Yeo CJ, Brody JR, Carr BI. Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway. J Gastroenterol Hepatol. 2010 Apr; 25(4):738-44. PMID: 19929921.
      Citations:    
    92. Brody JR, Witkiewicz AK, Yeo CJ, Gorospe M, Keen JC. The 'RNA-binding ome': future implications for chemotherapeutic efficacy. Future Oncol. 2009 Nov; 5(9):1317-9. PMID: 19903059.
      Citations:    
    93. Cotton RT, Li D, Scherer SE, Muzny DM, Hodges SE, Catania RL, Witkiewicz AK, Brody JR, Kennedy EP, Yeo CJ, Brunicardi FC, Gibbs RA, Gingras MC, Fisher WE. Single nucleotide polymorphism in RECQL and survival in resectable pancreatic adenocarcinoma. HPB (Oxford). 2009 Aug; 11(5):435-44. PMID: 19768149.
      Citations:    
    94. Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, Emmons RV, Witkiewicz AK. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle. 2009 Jun 15; 8(12):1930-4. PMID: 19448397.
      Citations:    
    95. Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res. 2009 Jun 1; 69(11):4567-72. PMID: 19487279.
      Citations:    
    96. Yeo TP, Hruban RH, Brody J, Brune K, Fitzgerald S, Yeo CJ. Assessment of "gene-environment" interaction in cases of familial and sporadic pancreatic cancer. J Gastrointest Surg. 2009 Aug; 13(8):1487-94. PMID: 19459017.
      Citations:    
    97. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg. 2009 May; 208(5):781-7; discussion 787-9. PMID: 19476837.
      Citations:    
    98. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009 Jun; 174(6):2023-34. PMID: 19411448.
      Citations:    
    99. Brody JR, Costantino CL, Potoczek M, Cozzitorto J, McCue P, Yeo CJ, Hruban RH, Witkiewicz AK. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol. 2009 May; 22(5):651-9. PMID: 19270646.
      Citations:    
    100. Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, Zhu H, van der Heijden MS, Winter JM, Wikiewicz AK, Yeo CJ, Kern SE. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Res. 2009 Feb 1; 69(3):984-91. PMID: 19155291.
      Citations:    
    101. Witkiewicz AK, Nguyen KH, Dasgupta A, Kennedy EP, Yeo CJ, Lisanti MP, Brody JR. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle. 2008 Oct; 7(19):3021-5. PMID: 18802406.
      Citations:    
    102. Showalter SL, Huang YH, Witkiewicz A, Costantino CL, Yeo CJ, Green JJ, Langer R, Anderson DG, Sawicki JA, Brody JR. Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol Ther. 2008 Oct; 7(10):1584-90. PMID: 19039293.
      Citations:    
    103. Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, Brody JR, Keen JC. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther. 2008 Sep; 7(9):1496-506. PMID: 18769129.
      Citations:    
    104. Williams TK, Yeo CJ, Brody J. Does this band make sense? Limits to expression based cancer studies. Cancer Lett. 2008 Nov 18; 271(1):81-4. PMID: 18602748.
      Citations:    
    105. Hucl T, Rago C, Gallmeier E, Brody JR, Gorospe M, Kern SE. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res. 2008 Jul 1; 68(13):5023-30. PMID: 18593900.
      Citations:    
    106. Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther. 2008 Jul; 7(7):986-94. PMID: 18443433.
      Citations:    
    107. Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, Brody JR. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg. 2008 May; 206(5):849-54; discussion 854-6. PMID: 18471709.
      Citations:    
    108. Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue CA, Farrance IK, Kern SE. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res. 2007 Oct 1; 67(19):9055-65. PMID: 17909009.
      Citations:    
    109. Brody JR, Witkiewicz A, Williams TK, Kadkol SS, Cozzitorto J, Durkan B, Pasternack GR, Yeo CJ. Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. Mod Pathol. 2007 Dec; 20(12):1238-44. PMID: 17906614.
      Citations:    
    110. Brody JR, Tulenko TN. No K01 offered from the NCI What's the message? Cancer Biol Ther. 2007 Jul; 6(7):1002; discussion 1003-4. PMID: 17611395.
      Citations:    
    111. Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir K, Kasparkova J, Brabec V, Bachman KE, Kern SE. High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. Cancer Res. 2007 Mar 1; 67(5):2169-77. PMID: 17332347.
      Citations:    
    112. Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE. Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer. Cancer Biol Ther. 2007 May; 6(5):654-60. PMID: 17387268.
      Citations:    
    113. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. Cancer Res. 2006 Oct 1; 66(19):9369-73. PMID: 17018589.
      Citations:    
    114. Brody JR, Gallmeier E, Yoshimura K, Hucl T, Kulesza P, Canto MI, Hruban RH, Schulick RD, Kern SE. A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes. Cancer Biol Ther. 2006 Aug; 5(8):923-7. PMID: 16855390.
      Citations:    
    115. Gallmeier E, Calhoun ES, Rago C, Brody JR, Cunningham SC, Hucl T, Gorospe M, Kohli M, Lengauer C, Kern SE. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology. 2006 Jun; 130(7):2145-54. PMID: 16762635.
      Citations:    
    116. Winter JM, Brody JR, Kern SE. Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature. Cancer Biol Ther. 2006 Apr; 5(4):360-70. PMID: 16575211.
      Citations:    
    117. van der Heijden MS, Brody JR, Elghalbzouri-Maghrani E, Zdzienicka MZ, Kern SE. Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers. BMC Genet. 2006; 7:3. PMID: 16417627.
      Citations:    
    118. van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res. 2005 Oct 15; 11(20):7508-15. PMID: 16243825.
      Citations:    
    119. Brody JR, Kern SE. History and principles of conductive media for standard DNA electrophoresis. Anal Biochem. 2004 Oct 1; 333(1):1-13. PMID: 15351274.
      Citations:    
    120. Brody JR, Calhoun ES, Gallmeier E, Creavalle TD, Kern SE. Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media. Biotechniques. 2004 Oct; 37(4):598, 600, 602. PMID: 15517972.
      Citations:    
    121. Brody JR, Kern SE. Stagnation and herd mentality in the biomedical sciences. Cancer Biol Ther. 2004 Sep; 3(9):903-10. PMID: 15326377.
      Citations:    
    122. van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol. 2004 Aug; 165(2):651-7. PMID: 15277238.
      Citations:    
    123. Van Der Heijden MS, Brody JR, Kern SE. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot. Cancer Biol Ther. 2004 Jun; 3(6):534-7. PMID: 15107617.
      Citations:    
    124. Kochevar GJ, Brody JR, Kadkol SS, Murphy KM, Pasternack GR. Identification of a functional mutation in pp32r1 (ANP32C). Hum Mutat. 2004 Jun; 23(6):546-51. PMID: 15146458.
      Citations:    
    125. Brody JR, Kern SE. Sodium boric acid: a Tris-free, cooler conductive medium for DNA electrophoresis. Biotechniques. 2004 Feb; 36(2):214-6. PMID: 14989083.
      Citations:    
    126. Brody JR, Kadkol SS, Hauer MC, Rajaii F, Lee J, Pasternack GR. pp32 reduction induces differentiation of TSU-Pr1 cells. Am J Pathol. 2004 Jan; 164(1):273-83. PMID: 14695340.
      Citations:    
    Brody's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (320)
    Explore
    _
    Co-Authors (50)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _